Drugs & Targets FDA approves Cytalux for identifying malignant ovarian cancer lesions December 03, 2021Vol.47 No.44
Drugs & Targets FDA grants orphan drug designation to UV1 cancer vaccine in metastatic melanoma December 03, 2021Vol.47 No.44
Guest EditorialHealth Equity To make clinical trials equitable, cancer groups evaluate restrictive eligibility criteria November 19, 2021Vol.47 No.43By Julia Beaver, Thomas S. Uldrick, Gwynn Ison, Suanna S. Bruinooge, Caroline Schenkel and Edward S. Kim
Drugs & Targets FDA approves Keytruda as adjuvant therapy for patients with RCC following nephrectomy November 19, 2021Vol.47 No.43
Drugs & Targets WVU gets FDA approval for clinical trial of drug to treat eye cancer ‘from the inside out’ November 19, 2021Vol.47 No.43
FreeHealth Equity Project Equity: FDA considers options to increase diverse enrollment in clinical trials November 12, 2021Vol.47 No.42By Matthew Bin Han Ong
Conversation with The Cancer LetterFreeHealth Equity FDA’s Lola Fashoyin-Aje: Stop getting stuck on the “risks” of diversity in drug development, it’s time to fix disparities in access November 12, 2021Vol.47 No.42By Matthew Bin Han Ong
Conversation with The Cancer LetterFreeHealth Equity NCTN group chairs, experts: Diverse representation of minorities in clinical trials and drug development saves lives November 12, 2021Vol.47 No.42By Matthew Bin Han Ong
Conversation with The Cancer Letter FDA’s review of “dangling indications” continues beyond PD-1 and PD-L1 drugs October 15, 2021Vol.47 No.38By Paul Goldberg
Trials & Tribulations Converting Cox hazard ratios with Cox-TEL to improve interpretation of drug efficacy in checkpoint inhibitor trials September 10, 2021Vol.47 No.33By Yu Shyr
